FUS and amyotrophic lateral sclerosis: Indeed, the intrathecal administration of an antisense oligonucleotide (ASO) reducing the expression of the gene has been proved to reduce the burden of FUS aggregates in neurons, which are a pathological hallmark of disease in patients carrying FUS mutations (FUS‐ALS).4